Carl June, MD, the Richard W. Vague Professor in Immunotherapy at Penn Medicine highlighted the lengthy and costly clinical approval process in the US and suggested a two-tier model for clinical trials at an FDA roundtable with life science researchers, entrepreneurs, and US health agency heads working in the cell and gene therapy field. Read more here.